



13/2022/AR

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
BioMaxima	Not rated	37.3	Not rated	Sylvia Jaśkiewicz, CFA +48 571 232 030 Mikołaj Stępień +48 504 949 345

Event: Signing a significant contract.

During Wednesday's trading the Company informed that it signed a contract for a delivery of diagnostic tests for SARS-CoV-2 worth PLN 94.9 million to the public finance sector unit. The management expects this contract to have a material impact on 1H22 financial results (the contract value exceeds the Company's preliminary unconsolidated sales for FY21 at PLN 78.5 million).

Expected impact: *The information was partially discounted on Wednesday.*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.